Condition
Mesothelioma|Pleural Mesothelioma
Estimated Enrollment: 55
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment
Study ID Numbers: PrE0505|ESR-15-10792
Study First Received: September 8, 2016
Last Updated: March 3, 2017
Estimated Primary Completion Date: August 2020
Primary Outcome Measures:
Overall Survival (OS)|Number of participants with treatment-related adverse events as assessed by CTCAE v4.03|Progression-Free Survival (PFS)|Time to Progression (TTP) on Durvalumab|Objective Response Rate (ORR)
Sponsors and Collaborators:
PrECOG, LLC.|AstraZeneca
Website Link: https://ClinicalTrials.gov/show/NCT02899195
